Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

“The addition of the durvalumab did not make treatment more morbid than chemotherapy alone, and it didn't change or increase the surgical complications you saw in the ward," says James W.F. Catto, MBChB, PhD, FRCS.

Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD. 

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.

Avoidance of prostate cancer screening linked to increased risk of PCSM

Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

New Directions in the Treatment of Non-Muscle Invasive Bladder Cancer 

Video Series

The Mental Health Impact of NMIBC Treatment: Management With Your Patient 

Videos

Experts provide an overview of non-muscle invasive bladder cancer (NMIBC) and common procedures for diagnosis. 

A Comprehensive Overview of NMIBC

Experts discuss the variability of non-muscle invasive bladder cancer (NMIBC) in terms of staging and risk stratification and how they navigate these diagnoses with their patients. 

Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships 

Experts discuss the evolving landscape of chemotherapy and immunotherapy options for patients with non-muscle invasive bladder cancer (NMIBC). 

Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

Experts discuss current trial data from several studies on non-muscle invasive bladder cancer (NMIBC).

New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

Experts consider other pipeline treatments for non-muscle invasive bladder cancer (NMIBC), including new injectable options being explored.

Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon 

Experts discuss logistical considerations when providing the best treatment to patients with non-muscle invasive bladder cancer (NMIBC).

Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC 

Experts discuss the mental impact of non-muscle invasive bladder cancer (NMIBC) treatment and approaches for developing a care network for those patients. 

Experts conclude their discussion on non-muscle invasive bladder cancer (NMIBC) highlighting practice considerations for today and the future. 

Navigating The Future of NMIBC Trails: Key Insights and Takeaways

The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP: 1.A Comprehensive Overview of NMIBC

EP: 2.Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP: 3.Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP: 4.New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP: 5.Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP: 6.Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP: 7.The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP: 8.Navigating The Future of NMIBC Trails: Key Insights and Takeaways